Skip to main content

Severe Mitral Valve Regurgitation (Disorder)

0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
Trancatheter Edge to Edge RepairN/A
NoRD Bio
NoRD BioMA - Cambridge
1 program
Trancatheter Edge to Edge RepairN/A1 trial
Active Trials
NCT05090540Enrolling By Invitation600Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NoRD BioTrancatheter Edge to Edge Repair

Clinical Trials (1)

Total enrollment: 600 patients across 1 trials

NCT05090540NoRD BioTrancatheter Edge to Edge Repair

Transcatheter Versus Standard Surgical Mitral Valve Operation for Secondary Mitral Regurgitation

Start: Jun 2017Est. completion: Dec 2025600 patients
N/AEnrolling By Invitation

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.